Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography

Thrombosis and Haemostasis

Volumn 98, Issue 6, 2007, Pages 1350-1356

  Tchaikovski, Svetlana N ^a   van Vliet, Huib A A M ^b   Thomassen, M Christella L G D ^a   Bertina, Rogier M ^b   Rosendaal, Frits R ^b   Sandset, Per Morten ^c   Helmerhorst, Frans M ^b   Tans, Guido ^a   Rosing, Jan ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

APC resistance; Oral contraceptives; Thrombin generation

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; CYPROTERONE ACETATE; DESOGESTREL; DROSPIRENONE; GESTODENE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PROTEIN S; PROTHROMBIN; THROMBIN;

ADULT; ANALYTIC METHOD; ARTICLE; AUTOMATION; CALIBRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; FEMALE; GENDER BIAS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOGRAPHY; TIME; VEIN THROMBOSIS;

EID: 36949027713     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-07-0439     Document Type: Article

References (39)

1. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vase Biol 2002; 22: 201-210.
2. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Br Med J 2001; 323: 131-134.
3. Dargaud Y, Trzeciak MC, Bordet JC, et al. Use of calibrated automated thrombinography +/- thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost 2006; 96: 562-567.
4. Hemker HC, Al Dieri R, De Smedt E, et al. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006; 96: 553-561.
5. Rotteveel RC, Roozendaal KJ, Eijsman L, et al. The influence of oral contraceptives on the time-integral of thrombin generation (thrombin potential). Thromb Haemost 1993; 70: 959-962.
6. Nicolaes GA, Thomassen MC, Tans G, et al. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals. Blood Coagul Fibrinolysis 1997; 8: 28-38.
7. Curvers J, Thomassen MC, Nicolaes GA, et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol 1999; 105: 88-94.
8. Rosing J, Middeldorp S, Curvcrs J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036-2040.
9. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
10. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
11. Tripodi A, Chantarangkul V, Mannucci PM. Hyper-prothrombinemia may result in scquired activated protein C reistance. Blood 2000; 96: 3295-3296.
12. Laffan MA, Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolysis 1996; 7: 761-765.
13. Curvers J, Thomassen MC, Rimmer J, et al. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost 2002; 88: 5-11.
14. Shu H, Wramsby M, Bokarewa M, et al. Decrease in protein C inhibitor activity and acquired APC resistance during normal pregnancy. J Thromb Thrombolysis 2000; 9: 277-281.
15. Olivieri O, Friso S, Manzato F, et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91: 465-470.
16. Rosing J, Tans G, Nicolaes GA, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-238.
17. Hoibraaten E, Mowinckel MC, de Ronde H, et al. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 2001; 115: 415-420.
18. Ehrenforth S, Radtke KP, Schaffer I. Acquired activated protein C-resistance in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 797-798.
19. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-1506.
20. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522.
21. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-1276.
22. Tans G, van Hylckama Vlieg A, Thomassen MC, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003; 122: 465-470.
23. Heniker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
24. Koenen RR, Christella M, Thomassen LG, et al. Effect of oral contraceptives on the anticoagulant activity of protein S in plasma. Thromb Haemost 2005; 93: 853-859.
25. van Vliet HA, Frolich M, Christella M, et al. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod 2005; 20: 563-568.
26. van Vliet HA, Winkel TA, Noort I, et al. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost 2004; 2: 2060-2062.
27. Bertina RM, van der Marel-van Nieuwkoop W, Loeliger EA. Spectrophotometric assays of prothrombin in plasma of patients using oral anticoagulants. Thromb Haemost 1979; 42: 1296-1305.
28. Dahm A, Van Hylckama Vlieg A, Bendz B, et al. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003; 101: 4387-4392.
29. Koster T, Rosendaal FR, Briet E, et al. Protein C deficiency in a controlled series of unselected out-patients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85: 2756-2761.
30. Giri TK, Hillarp A, Hardig Y, et al. A new direct, fast and quantitative enzyme-linked ligandsorbent assay for measurement of free protein S antigen. Thromb Haernost 1998; 79: 767-772.
31. Brugge JM, Tans G, Rosing J, et al. Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels. Thromb Haemost 2006; 95: 236-242.
32. Kemmeren JM, Algra A, Meijers JC, et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood 2004; 103: 927-933.
33. Newton JR. Classification and comparison of oral contraceptives containing new generation progestogens. Hum Reprod Update 1995; 1: 231-263.
34. de Visser MC, van Hylckama Vlieg A, Tans G, et al. Determinants of the APTT- and ETP-based APC sensitivity tests. J Thromb Haernost 2005; 3: 1488-1494.
35. Gris JC, Jamin C, Benifla JL, et al. APC resistance and third-generation oral contraceptives: Acquired resistance to activated protein C, oral contraceptives and the risk of thromboembolic disease. Hum Reprod 2001; 16: 3-8.
36. Gris JC, Nouvellon-Cochery E, Mares P. Increased resistance to activated protein C in women taking third-generation oral contraceptives? Blood 2004; 104: 1907; author reply 1908-1909.
37. Tans G, Curvers J, Middeldorp S, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84: 15-21.
38. Middeldorp S, Meijers JC, van den Ende AE, et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84: 4-8.
39. Hezard N, Bouaziz-Borgi L, Remy MG, et al. Utility of thrombin-generation assay in the screening of factor V G1691A (Leiden) and prothrombin G20210A mutations and protein S deficiency. Clin Chem 2006; 52: 665-670.